Patents Examined by Mukul Ranjan
  • Method for treating macrophage pathogen infections by TGF-B antagonists
    Patent number: 5730976
    Abstract: There is disclosed a method of treating a mammal infected with a macrophage pathogen comprising administering an effective amount of a TGF-.beta. antagonist. Macrophage pathogens include any pathogenic microorganism that replicates within macrophage cell hosts as their exclusive or primary host cells. TGF-.beta. antagonists include blocking antibodies specific for a human TGF-.beta., soluble TGF-.beta. receptors, protease inhibitors that inactivate a protease responsible for activating a precursor TGF-.beta. into an active, mature TGF-.beta., and combinations thereof.
    Type: Grant
    Filed: August 5, 1996
    Date of Patent: March 24, 1998
    Assignee: Corixa Corporation
    Inventor: Steven G. Reed
  • Isolated nucleic acid encoding receptor-like TGF-.beta.1 binding protein
    Patent number: 5731200
    Abstract: The invention relates to a family of substantially pure, receptor like TGF-.beta.1 binding glycoproteins. These molecules are characterized by molecular masses of 160 kd, 70-80 kd, and 30-40 kd as determined by SDS-PAGE, and the ability to bind the TGF-.beta.1 molecule. This family of molecules is useful in identifying and/or quantifying TGF-.beta.1 in a sample, as well as inhibiting its effect on cells. Also described are nucleic acid sequences which code for the protein monomer making up the molecules.
    Type: Grant
    Filed: December 5, 1995
    Date of Patent: March 24, 1998
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Hidenori Ichijo, Kohei Miyazono, Lars Ronnstrand, Ulf Hellman, Christer Wernstedt, Carl-Henrik Heldin
  • MADD, a TNF receptor death domain ligand protein
    Patent number: 5712381
    Abstract: Novel TNF receptor death domain ("TNF-R1-DD") ligand proteins are disclosed. Polynucleotides encoding the TNF-R1-DD ligand protein are also disclosed, along with vectors, host cells, and methods of making the TNF-R1-DD ligand protein. Pharmaceutical compositions containing the TNF-R1-DD ligand protein, methods of treating inflammatory conditions, and methods of inhibiting TNF-R death domain binding are also disclosed. Methods of identifying inhibitors of TNF-R death domain binding and inhibitors identified by such methods are also disclosed.
    Type: Grant
    Filed: August 15, 1996
    Date of Patent: January 27, 1998
    Assignee: Genetics Institute, Inc.
    Inventors: Lih-Ling Lin, Jennifer Chen, Andrea R. Schievella, James Graham
  • LDL receptor analog protein and DNA coding therefor
    Patent number: 5665872
    Abstract: The present invention is drawn to a DNA encoding a novel LDL receptor-analog. LDL receptors participate in lipoprotein metabolism, which is a critical factor in the onset of arteriosclerosis. The invention provides DNA having the nucleotide sequences shown by SEQ ID NOS: 1 and 5, which encode rabbit and human LDL receptor analog proteins having the sequences shown in SEQ ID NOS: 3 and 7 respectively.
    Type: Grant
    Filed: October 8, 1996
    Date of Patent: September 9, 1997
    Assignee: Kowa Co., Ltd.
    Inventors: Yasushi Saito, Akio Iwasaki, Koichi Arai, Hiroyuki Yamazaki